![Sustainability | Free Full-Text | An Interdisciplinary Systematic Review on Sustainability in Tunneling—Bibliometrics, Challenges, and Solutions Sustainability | Free Full-Text | An Interdisciplinary Systematic Review on Sustainability in Tunneling—Bibliometrics, Challenges, and Solutions](https://www.mdpi.com/sustainability/sustainability-14-02275/article_deploy/html/images/sustainability-14-02275-g001.png)
Sustainability | Free Full-Text | An Interdisciplinary Systematic Review on Sustainability in Tunneling—Bibliometrics, Challenges, and Solutions
Upon reconnecting after connection "lost", the connection.onopen is NOT triggered... · Issue #201 · crossbario/autobahn-js · GitHub
![Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems](https://www.mdpi.com/applsci/applsci-12-04300/article_deploy/html/images/applsci-12-04300-g001-550.jpg)
Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems
![Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems](https://www.mdpi.com/applsci/applsci-12-04300/article_deploy/html/images/applsci-12-04300-g001.png)
Applied Sciences | Free Full-Text | A Study on Vehicle Monitoring Service Using Attribute-Based Security Scheme in Cyber–Physical Systems
![Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial - The Lancet Neurology Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/26226a78-76e7-4cab-8897-6581d08d00a2/gr1_lrg.jpg)